The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Open accessAbstract
BACKGROUND: Romosozumab is a monoclonal antibody that binds to and inhibits sclerostin, increases bone formation, and decreases bone resorption. METHODS: We enrolled 4093 postmenopausal women with osteoporosis and a fragility fracture and randomly assigned them in a 1:1 ratio to receive monthly subcutaneous romosozumab (210 mg) or weekly oral alendronate (70 mg) in a blinded fashion for 12 months, followed by open-label alendronate in both groups. The primary end points were the cumulative incidence of new vertebral fracture at 24 months and the cumulative incidence of clinical fracture (nonvertebral and symptomatic vertebral fracture) at the time of the primary analysis (after clinical fractures had been confirmed in ≥330 patients). Secondary end points included the incidences of nonvertebral and hip fracture at the time of the primary analysis. Serious cardiovascular adverse events, osteonecrosis of the jaw, and atypical femoral fractures were adjudicated. RESULTS: Over a period of 24 months, a 48% lower risk of new vertebral fractures was observed in the romosozumab-to-alendronate group (6.2% [127 of 2046 patients]) than in the alendronate-to-alendronate group (11.9% [243 of 2047 patients]) (P<0.001). Clinical fractures occurred in 198 of 2046 patients (9.7%) in the romosozumab-to-alendronate group versus 266 of 2047 patients (13.0%) in the alendronate-to-alendronate group, representing a 27% lower risk with romosozumab (P<0.001). The risk of nonvertebral fractures was lower by 19% in the romosozumab-to-alendronate group than in the alendronate-to-alendronate group (178 of 2046 patients [8.7%] vs. 217 of 2047 patients [10.6%]; P=0.04), and the risk of hip fracture was lower by 38% (41 of 2046 patients [2.0%] vs. 66 of 2047 patients [3.2%]; P=0.02). Overall adverse events and serious adverse events were balanced between the two groups. During year 1, positively adjudicated serious cardiovascular adverse events were observed more often with romosozumab than with alendronate (50 of 2040 patients [2.5%] vs. 38 of 2014 patients [1.9%]). During the open-label alendronate period, adjudicated events of osteonecrosis of the jaw (1 event each in the romosozumab-to-alendronate and alendronate-to-alendronate groups) and atypical femoral fracture (2 events and 4 events, respectively) were observed. CONCLUSIONS: In postmenopausal women with osteoporosis who were at high risk for fracture, romosozumab treatment for 12 months followed by alendronate resulted in a significantly lower risk of fracture than alendronate alone. (Funded by Amgen and others; ARCH ClinicalTrials.gov number, NCT01631214 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, major cardiac events were observed in the ARCH study, while headaches, arthralgia, and injection site reactions were also observed [89,90].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As of 2021, it has reached Phase III trials, which have shown an increase in bone mineral density and a decrease in vertebral and hip fractures.”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“The ARCH study showed a 48% lower risk of new vertebral fractures in the group that received romosozumab and alendronate than in the alendronate-only group [89].”
From Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics (2023) · cites this paper as [89]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Epidemiology and outcomes of osteoporotic fractures
Cummings, S. R., & Melton, L. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08657-9 · Cited by 3,821
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489
Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
Self-citationReginster, J.-Y., Minne, H. W., Sorensen, O. H., Hooper, M., Roux, C., Brandi, M. L., Lund, B., Ethgen, D., Pack, S., Roumagnac, I., et al. (2000) · Osteoporosis International · doi:10.1007/s001980050010 · Cited by 1,580
Self-citationRomosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Self-citationBrunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Flagged first, then by citations
Cited by
Sorted by citations
Compston, J. E., McClung, M. R., & Leslie, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32112-3 · Cited by 2,449
The clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
Self-citationRuggiero, S. L., Dodson, T. B., Aghaloo, T. L., Carlson, E. R., Ward, B. B., & Kademani, D. (2022) · Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.joms.2022.02.008 · Cited by 1,209
Camacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., et al. (2020) · Endocrine Practice · doi:10.4158/gl-2020-0524suppl · Cited by 1,182
Camacho, P. M., Petak, S. M., Binkley, N., Clarke, B. L., Harris, S. T., Hurley, D. L., Kleerekoper, M., Lewiecki, E. M., Miller, P. D., Narula, H. S., et al. (2016) · Endocrine Practice · doi:10.4158/ep161435.esgl · Cited by 1,140
Wnt signaling in development and tissue homeostasis
Steinhart, Z., & Angers, S. (2018) · Development · doi:10.1242/dev.146589 · Cited by 821
Drug therapy for osteoporosis in older adults
Reid, I. R., & Billington, E. O. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02646-5 · Cited by 736
Kenkre, J. E., & Bassett, J. H. D. (2018) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563218759371 · Cited by 772
UK clinical guideline for the prevention and treatment of osteoporosis
Gregson, C. L., Armstrong, D. J., Bowden, J., Cooper, C., Edwards, J., Gittoes, N. J. L., Harvey, N., Kanis, J., Leyland, S., Low, R., et al. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01061-5 · Cited by 593
Understanding the Bone in Cancer Metastasis
Fornetti, J., Welm, A. L., & Stewart, S. A. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3618 · Cited by 534
Advances in pathogenesis and therapeutic strategies for osteoporosis
Song, S., Guo, Y., Yang, Y., & Fu, D. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108168 · Cited by 476
(2021) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001831 · Cited by 481
Shoback, D., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Eastell, R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa048 · Cited by 452
Lin, H., Sohn, J., Shen, H., Langhans, M. T., & Tuan, R. S. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.06.026 · Cited by 454
WNT–β-catenin signalling — a versatile player in kidney injury and repair
Schunk, S. J., Floege, J., Fliser, D., & Speer, T. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00343-w · Cited by 448
Walker, M. D., & Shane, E. J. (2023) · New England Journal of Medicine · doi:10.1056/nejmcp2307353 · Cited by 431
Bone Turnover Markers: Basic Biology to Clinical Applications
Schini, M., Vilaça, T., Gossiel, F., Salam, S., & Eastell, R. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac031 · Cited by 434
Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures
Kanis, J. А., Harvey, N. C., McCloskey, E. V., Bruyère, O., Veronese, N., Lorentzon, M., Cooper, C. C., Rizzoli, R., Adib, G., Al‐Daghri, N. M., et al. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05176-3 · Cited by 412
Self-citationDiagnosis and management of bone fragility in diabetes: an emerging challenge
Ferrari, S., Abrahamsen, B., Napoli, N., Åkesson, K., Chandran, M., Eastell, R., Fuleihan, G. E., Josse, R. G., Kendler, D. L., Kraenzlin, M., et al. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4650-2 · Cited by 409
Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials
Bouxsein, M., Eastell, R., Lui, L., Wu, L., de Papp, A. E., Grauer, A., Marín, F., Cauley, J. A., Bauer, D. C., Black, D. M., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3641 · Cited by 357
Self-citationThe Regulation of Bone Metabolism and Disorders by Wnt Signaling
Maeda, K., Kobayashi, Y., Koide, M., Uehara, S., Okamoto, M., Ishihara, A., Kayama, T., Saito, M., & Marumo, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225525 · Cited by 360
Arceo-Mendoza, R. M., & Camacho, P. M. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.03.009 · Cited by 300
Ayers, C. K., Kansagara, D. L., Lazur, B. H., Fu, R. F., Kwon, A., & Harrod, C. S. (2023) · Annals of Internal Medicine · doi:10.7326/m22-0684 · Cited by 297
Molecular Mechanisms and Emerging Therapeutics for Osteoporosis
Noh, J., Yang, Y. D., & Jung, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207623 · Cited by 299
Functional Biomaterials for Bone Regeneration: A Lesson in Complex Biology
Armiento, A. R., Hatt, L. P., Rosenberg, G. S., Thompson, K., & Stoddart, M. J. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909874 · Cited by 281
Long-term and sequential treatment for osteoporosis
Foessl, I., Dimai, H. P., & Obermayer-Pietsch, B. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00866-9 · Cited by 273
Osteoporosis: Pathophysiology and therapeutic options
Föger‐Samwald, U., Dovjak, P., Azizi-Semrad, U., Kerschan‐Schindl, K., & Pietschmann, P. (2020) · EXCLI journal · doi:10.17179/excli2020-2591 · Cited by 284
The osteocyte as a signaling cell
Delgado‐Calle, J., & Bellido, T. (2021) · Physiological Reviews · doi:10.1152/physrev.00043.2020 · Cited by 280
Morin, S. N., Leslie, W. D., & Schousboe, J. T. (2025) · JAMA · doi:10.1001/jama.2025.6003 · Cited by 284
Qaseem, A., Hicks, L. A., Etxeandia‐Ikobaltzeta, I., Shamliyan, T., & Cooney, T. G. (2023) · Annals of Internal Medicine · doi:10.7326/m22-1034 · Cited by 253
Osteoporosis pathogenesis and treatment: existing and emerging avenues
Liang, B., Burley, G., Lin, S., & Shi, Y. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00371-3 · Cited by 250
Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review
Kendler, D. L., Cosman, F., Stad, R. K., & Ferrari, S. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01936-y · Cited by 249
Kaplon, H., & Reichert, J. M. (2018) · mAbs · doi:10.1080/19420862.2018.1415671 · Cited by 258
The challenges of diagnosing osteoporosis and the limitations of currently available tools
Choksi, P. U., Jepsen, K. J., & Clines, G. A. (2018) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-018-0062-7 · Cited by 249
Osteoporosis and fractures in women: the burden of disease
Lorentzon, M., Johansson, H., Harvey, N. C., Liu, E., Vandenput, L., McCloskey, E. V., & Kanis, J. А. (2021) · Climacteric · doi:10.1080/13697137.2021.1951206 · Cited by 257
Self-citationShapiro, C. L., Poznak, C. H. V., Lacchetti, C., Kirshner, J. J., Eastell, R., Gagel, R. F., Smith, S. R., Edwards, B. J.-A., Frank, E. S., Lyman, G. H., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01696 · Cited by 243
McClung, M. R., Brown, J. P., Díez‐Pérez, A., Resch, H., Caminis, J. N., Meisner, P. D., Bolognese, M. A., Goemaere, S., Bone, H. G., Zanchetta, J., et al. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3452 · Cited by 242
Self-citationBlack, D. M., Bauer, D. C., Vittinghoff, E., Lui, L.-Y., Grauer, A., Marin, F., Khosla, S., de Papp, A., Mitlak, B., Cauley, J. A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30159-5 · Cited by 228
Self-citationUpdate on Osteoporosis Screening and Management
Anam, A. K., & Insogna, K. L. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.05.016 · Cited by 244
Händel, M. N., Cardoso, I., von Bülow, C., Rohde, J. F., Ussing, A., Nielsen, S. M., Christensen, R., Body, J., Brandi, M. L., Díez‐Pérez, A., et al. (2023) · BMJ · doi:10.1136/bmj-2021-068033 · Cited by 236
Self-citationOsteoporosis: Mechanism, Molecular Target and Current Status on Drug Development
Li, H., Xiao, Z., Quarles, L. D., & Li, W. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867327666200330142432 · Cited by 226
Bone, H. G., Cosman, F., Miller, P. D., Williams, G. C., Hattersley, G., Hu, M., Fitzpatrick, L. A., Mitlak, B., Papapoulos, S. E., Rizzoli, R., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00163 · Cited by 215
Self-citationOverview of treatment approaches to osteoporosis
Langdahl, B. L. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15024 · Cited by 222
Evenepoel, P., Cunningham, J., Ferrari, S., Haarhaus, M. L., Javaid, M. K., Lafage‐Proust, M., Prieto‐Alhambra, D., Ureña, P., Cannata-Andía, J. B., Vervloet, M. G., et al. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa192 · Cited by 226
Lewiecki, E. M., Dinavahi, R. V., Lazaretti-Castro, M., Ebeling, P. R., Adachi, J. D., Miyauchi, A., Gielen, E., Milmont, C. E., Libanati, C. R., & Grauer, A. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3622 · Cited by 208
Self-citationTreating osteoporosis to prevent fractures: current concepts and future developments
Lorentzon, M. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12873 · Cited by 211
Self-citationBlack, D. M., Abrahamsen, B., Bouxsein, M., Einhorn, T. A., & Napoli, N. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00001 · Cited by 207
Long-Term Treatment of Postmenopausal Osteoporosis
Brown, J. P. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.301 · Cited by 203
Pathophysiology and treatment of osteoporosis: Challenges for clinical practice in older people
Barnsley, J., Buckland, G., Chan, P. E., Ong, A., Ramos, A. S., Baxter, M., Laskou, F., Dennison, E. M., Cooper, C., & Patel, H. P. (2021) · Aging Clinical and Experimental Research · doi:10.1007/s40520-021-01817-y · Cited by 199
Yu, Y., Wang, L., Ni, S., Li, D., Liu, J., Chu, H. Y., Zhang, N., Sun, M., Li, N., Ren, Q., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31997-8 · Cited by 197
Zhu, X., Bai, W.-Y., & Zheng, H. (2021) · Bone Research · doi:10.1038/s41413-021-00143-3 · Cited by 198
State of the art in osteoporosis risk assessment and treatment
Liu, J., Curtis, E. M., Cooper, C. C., & Harvey, N. C. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01041-6 · Cited by 198
Cell Biology of Canonical Wnt Signaling
Albrecht, L. V., Tejeda‐Muñoz, N., & Robertis, E. M. D. (2021) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-120319-023657 · Cited by 192
Migliorini, F., Maffulli, N., Colarossi, G., Eschweiler, J., Tingart, M., & Betsch, M. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02678-x · Cited by 184
Chavassieux, P., Chapurlat, R. D., Portero-Muzy, N., Roux, J.-P., Garcia, P., Brown, J. P., Libanati, C. R., Boyce, R. W., Wang, A., & Grauer, A. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3735 · Cited by 179
Self-citationOsteoporosis in Rheumatic Diseases
Adami, G., Fassio, A., Rossini, M., Caimmi, C., Giollo, A., Orsolini, G., Viapiana, O., & Gatti, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235867 · Cited by 179
Targeting strategies for bone diseases: signaling pathways and clinical studies
Xu, H., Wang, W., Liu, X., Huang, W. H., Chen, Z., Xu, Y., Yang, H., Bai, J., & Geng, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01467-8 · Cited by 175
Disuse Osteoporosis: Clinical and Mechanistic Insights
Rolvien, T., & Amling, M. (2021) · Calcified Tissue International · doi:10.1007/s00223-021-00836-1 · Cited by 176
Davis, S., Simpson, E. L., Hamilton, J., James, M. M., Rawdin, A., Wong, R., Goka, E., Gittoes, N. J. L., & Selby, P. L. (2020) · Health Technology Assessment · doi:10.3310/hta24290 · Cited by 170
Wang, Z., Luo, Z., Li, F., Cao, J., Rao, S., Liu, Y.-W., Wang, Y., Zhu, G., Gong, J.-S., Zou, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29191-x · Cited by 165
RetractedDeterminants of imminent fracture risk in postmenopausal women with osteoporosis
Barron, R., Oster, G., Grauer, A., Crittenden, D. B., & Weycker, D. A. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05294-3 · Cited by 160
Self-citationInsights and implications of sexual dimorphism in osteoporosis
Zhang, Y., Xie, N., Sun, X., Nice, E. C., Liou, Y., Huang, C., Zhu, H., & Shen, Z. (2024) · Bone Research · doi:10.1038/s41413-023-00306-4 · Cited by 164
Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024
Cosman, F., Lewiecki, E. M., Eastell, R., Ebeling, P. R., de Beur, S. M. J., Langdahl, B. L., Rhee, Y., Fuleihan, G. E., Kiel, D. P., Schousboe, J. T., et al. (2024) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjae119 · Cited by 157
Bone Health and Osteoporosis Prevention and Treatment
MUÑOZ, M., ROBINSON, K., & Shibli-Rahhal, A. A. (2020) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000572 · Cited by 160
A decade of FRAX: how has it changed the management of osteoporosis?
Kanis, J. А., Harvey, N. C., Johansson, H., Liu, E., Vandenput, L., Lorentzon, M., Leslie, W. D., & McCloskey, E. V. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-019-01432-y · Cited by 157
Self-citationSide effects of drugs for osteoporosis and metastatic bone disease
Skjødt, M. K., Frost, M., & Abrahamsen, B. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13759 · Cited by 153
Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders
Marini, F., Giusti, F., Palmini, G., & Brandi, M. L. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06523-7 · Cited by 154
Self-citationIs there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?
Rozenberg, S., Al-Daghri, N., Aubertin-Leheudre, M., Brandi, M.-L., Cano, A., Collins, P., Cooper, C., Genazzani, A. R., Hillard, T., Kanis, J. A., et al. (2020) · Osteoporosis International · doi:10.1007/s00198-020-05497-8 · Cited by 149
Self-citationPharmacological Management of Postmenopausal Osteoporosis: a Level I Evidence Based - Expert Opinion
Migliorini, F., Colarossi, G., Baroncini, A., Eschweiler, J., Tingart, M., & Maffulli, N. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1851192 · Cited by 149
Osteoporosis: Molecular Pathology, Diagnostics, and Therapeutics
Adejuyigbe, B., Kallini, J., Chiou, D., & Kallini, J. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914583 · Cited by 148
Testosterone Treatment and Fractures in Men with Hypogonadism
Snyder, P. J., Bauer, D. C., Ellenberg, S. S., Cauley, J. A., Buhr, K. A., Bhasin, S., Miller, M. G., Khan, N., Li, X., & Nissen, S. E. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2308836 · Cited by 145
The Activity of Peptides of the Calcitonin Family in Bone
Naot, D., Musson, D. S., & Cornish, J. (2019) · Physiological Reviews · doi:10.1152/physrev.00066.2017 · Cited by 141
New Frontiers in Osteoporosis Therapy
Cheng, C., Wentworth, K. L., & Shoback, D. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-052218-020620 · Cited by 141
Bhattoa, H. P., Vasikaran, S. D., Trifonidi, I., Kapoula, G., Lombardi, G., Jørgensen, N. R., Pikner, R., Miura, M., Chapurlat, R. D., Hiligsmann, M., et al. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07422-3 · Cited by 148
Evidence-Based Guideline for the management of osteoporosis in men
Fuggle, N. R., Beaudart, C., Bruyère, O., Abrahamsen, B., Al‐Daghri, N. M., Burlet, N., Chandran, M., Rosa, M. M., Cortet, B., Demonceau, C., et al. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01094-9 · Cited by 145
Bone-targeting AAV-mediated silencing of Schnurri-3 prevents bone loss in osteoporosis
Yang, Y.-S., Xie, J., Wang, D., Kim, J., Tai, P. W. L., Gravallese, E. M., Gao, G., & Shim, J. (2019) · Nature Communications · doi:10.1038/s41467-019-10809-6 · Cited by 140
Bone Mineral Density: Clinical Relevance and Quantitative Assessment
Haseltine, K., Chukir, T., Smith, P. J., Jacob, J. T., Bilezikian, J. P., & Farooki, A. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.256180 · Cited by 138
Migliorini, F., Maffulli, N., Spiezia, F., Peretti, G. M., Tingart, M., & Giorgino, R. (2021) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-021-02497-0 · Cited by 138
Subarajan, P., Arceo-Mendoza, R. M., & Camacho, P. M. (2024) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2024.08.008 · Cited by 136
Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures
Starr, J., Tay, D., & Shane, E. J. (2018) · Current Osteoporosis Reports · doi:10.1007/s11914-018-0464-6 · Cited by 132
Kendler, D. L., Bone, H. G., Massari, F., Gielen, E., Palacios, S., Maddox, J., Yan, C., Yue, S. V., Dinavahi, R. V., Libanati, C. R., et al. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05146-9 · Cited by 129
Self-citationThe 2024 UK clinical guideline for the prevention and treatment of osteoporosis
Gregson, C. L., Armstrong, D., Avgerinou, C., Bowden, J., Cooper, C. C., Douglas, L., Edwards, J., Gittoes, N. J. L., Harvey, N. C., Kanis, J. A., et al. (2025) · Archives of Osteoporosis · doi:10.1007/s11657-025-01588-3 · Cited by 136
Management of Osteoporosis in CKD
Khairallah, P., & Nickolas, T. L. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11031017 · Cited by 127
Antiresorptive and anabolic agents in the prevention and reversal of bone fragility
Seeman, E., & Martin, T. J. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0172-3 · Cited by 127
Anastasilakis, A. D., Pοlyzos, S. A., & Makras, P. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0056 · Cited by 125
Anabolic Therapies in Osteoporosis and Bone Regeneration
Rußow, G., Jahn, D., Appelt, J., Märdian, S., Tsitsilonis, S., & Keller, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010083 · Cited by 128
Changes in the osteocyte lacunocanalicular network with aging
Tiede-Lewis, L. M., & Dallas, S. L. (2019) · Bone · doi:10.1016/j.bone.2019.01.025 · Cited by 122
WNT Signaling and Bone: Lessons From Skeletal Dysplasias and Disorders
Huybrechts, Y., Mortier, G. R., Boudin, E., & Hul, W. V. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00165 · Cited by 123
Age Related Osteoporosis: Targeting Cellular Senescence
Föger‐Samwald, U., Kerschan‐Schindl, K., Butylina, M., & Pietschmann, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052701 · Cited by 121
Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review
Ukon, Y., Makino, T., Kodama, J., Tsukazaki, H., Tateiwa, D., Yoshikawa, H., & Kaito, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102557 · Cited by 121
Cardiovascular Calcification Heterogeneity in Chronic Kidney Disease
Hutcheson, J. D., & Goettsch, C. (2023) · Circulation Research · doi:10.1161/circresaha.123.321760 · Cited by 125
Bovijn, J., Krebs, K., Chen, C.-Y., Boxall, R., Censin, J. C., Ferreira, T., Pulit, S. L., Glastonbury, C. A., Laber, S., Millwood, I. Y., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay6570 · Cited by 119
Lv, F., Cai, X., Yang, W., Gao, L., Chen, L., Wu, J., & Ji, L. (2019) · Bone · doi:10.1016/j.bone.2019.115121 · Cited by 121
Romosozumab and antiresorptive treatment: the importance of treatment sequence
Cosman, F., Kendler, D. L., Langdahl, B. L., Leder, B. Z., Lewiecki, E. M., Miyauchi, A., Rojeski, M., McDermott, M., Oates, M. K., Milmont, C. E., et al. (2022) · Osteoporosis International · doi:10.1007/s00198-021-06174-0 · Cited by 118
Assessment and treatment of osteoporosis and fractures in type 2 diabetes
Sheu, A., Greenfield, J. R., & White, C. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.02.006 · Cited by 119
Yu, M. S., Qin, K. H., Fan, J., Zhao, G., Zhao, P., Zeng, W., Chen, C., Wang, A., Wang, Y., Zhong, J., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.04.042 · Cited by 125
The Development of Molecular Biology of Osteoporosis
Gao, Y., Patil, S., & Jia, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158182 · Cited by 116
Medical Treatment for Osteoporosis: From Molecular to Clinical Opinions
Chen, L.-R., Ko, N.-Y., & Chen, K.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092213 · Cited by 116
Ferrari, S., Libanati, C. R., Lin, C. J. F., Brown, J. P., Cosman, F., Czerwinski, E. J., de Gregorio, L. H., Malouf, J., Reginster, J.-Y., Wang, A., et al. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3722 · Cited by 116
Regulation of bone homeostasis: signaling pathways and therapeutic targets
Wu, Z., Li, W., Jiang, K., Lin, Z., Qian, C., Wu, M., Xia, Y., Li, N., Zhang, H., Xiao, H.-X., et al. (2024) · MedComm · doi:10.1002/mco2.657 · Cited by 121
Metadata
- Authors
- Saag, K. G., Petersen, J., Brandi, M. L., Karaplis, A. C., Lorentzon, M., Thomas, T., Maddox, J., Fan, M., Meisner, P. D., & Grauer, A.
- Affiliations
- Inserm (FR)
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-10-12
- Volume
- 377
- Issue
- 15
- Pages
- 1417-1427
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2754720807
- Cited by
- 1,544
- References
- 31
- Citations by year
- 2026: 204 · 2025: 216 · 2024: 210 · 2023: 148 · 2022: 179 · 2021: 172 · 2020: 185 · 2019: 114 · 2018: 94 · 2017: 19
- FWCI
- 123.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Gilead Sciences
- Teva Pharmaceutical Industries
- Radius Health
- Medac
- Chugai Pharmaceutical
- Amgen Canada
- UCB Pharma
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- romosozumab, alendronate, osteoporosis, fracture prevention, sclerostin inhibition, postmenopausal women, vertebral fractures, hip fracture, non-vertebral fractures, bisphosphonates, cardiovascular adverse events, osteonecrosis of the jaw, atypical femoral fractures, bone formation, bone resorption, fragility fractures, open-label extension
- MeSH terms
- Aged, Antibodies, Monoclonal, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Risk, Bone Density, Osteoporosis, Postmenopausal, Incidence, Least-Squares Analysis, Spinal Fractures, Bone Remodeling, Alendronate, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
